These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 10914239

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. [Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
    Verdy E, Debrix I, Benomar A, Becker A, Flahault A.
    Presse Med; 2007 May; 36(5 Pt 1):786-93. PubMed ID: 17303370
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Danaparoid sodium.
    Acostamadiedo JM, Iyer UG, Owen J.
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats.
    Fujishima Y, Yokota K, Sukamoto T.
    Thromb Res; 1998 Sep 01; 91(5):221-7. PubMed ID: 9755834
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
    Hale LP, Smith K, Braden GA, Owen J.
    Cathet Cardiovasc Diagn; 1998 Nov 01; 45(3):318-22. PubMed ID: 9829897
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
    Fernandes P, Mayer R, MacDonald JL, Cleland AG, Hay-McKay C.
    Perfusion; 2000 Nov 01; 15(6):531-9. PubMed ID: 11131218
    [Abstract] [Full Text] [Related]

  • 55. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B, Tardy-Poncet B, Viallon A, Piot M, Mazet E.
    Thromb Haemost; 1998 Sep 01; 80(3):530. PubMed ID: 9759647
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
    Tardy-Poncet B, Wolf M, Lasne D, Bauters A, Ffrench P, Elalamy I, Tardy B.
    Intensive Care Med; 2009 Aug 01; 35(8):1449-53. PubMed ID: 19350215
    [Abstract] [Full Text] [Related]

  • 58. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
    Hill GR, Hickton C, Henderson S, Patton WN.
    Clin Lab Haematol; 1997 Jun 01; 19(2):155-7. PubMed ID: 9218159
    [Abstract] [Full Text] [Related]

  • 59. Ardeparin and danaparoid for prevention of deep vein thrombosis.
    Med Lett Drugs Ther; 1997 Oct 10; 39(1011):94-5. PubMed ID: 9379998
    [No Abstract] [Full Text] [Related]

  • 60. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome.
    Tardy/Poncet B, Mahul P, Beraud AM, Favre JP, Tardy B, Guyotat D.
    Br J Haematol; 1995 Aug 10; 90(4):969-70. PubMed ID: 7669684
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.